Highlights
- •Herd immunity is still a hot topic for COVID-19 globally
- •It is crucial in relation to advancing COVID-19 vaccination
- •Seroprevalence data are important in epidemiological situation analysis
- •This study analyzed data from different seroprevalence studies from South America
- •There was high seroprevalence in different countries in this region
Abstract
Herd immunity is considered to be a relevant aspect of COVID-19 epidemiology. In this regard, seroprevalence studies are essential for understanding how far countries and regions are from that potential point. This study analyzed seroprevalence data in nine studies from South America, which is a region that has been badly affected by COVID-19. Seroprevalence values were high, with percentages up to 70.0% (95% CI 67.0-73.4%) in Iquitos, Peru. A meta-analysis of such data enabled a pooled seroprevalence to be obtained, estimated at 33.6% (95% CI 28.6-38.5%). Despite this, the COVID-19 pandemic in South America continues to significantly affect countries such as Brazil, Colombia, and Peru.
Keywords
Introduction
There has been intense discussion about the importance of reaching herd immunity to achieve global population protection status against SARS-CoV-2/COVID-19. For that reason, vaccination coverage and seroprevalence studies are increasing around the world; some of them have shown an increase in the seroprevalence of different populations. For example, a recent study in Jordan (
Sughayer et al., 2021
) stated the importance of seroprevalence studies for SARS-CoV-2 infection among healthy blood donors. The current study analyzed some seroprevalence data in South America, which is a region that has also been badly affected by coronavirus disease 2019 (COVID-19).Since it was first identified, COVID-19 has caused millions of people to be infected and thousands of deaths to occur worldwide. Therefore, to better manage the disease, health authorities need to know the prevalence. Although the RT-qPCR is the gold standard for its diagnosis, serological methods have the advantage of detecting the actual extent of the disease, due to the permanence of anti-IgM and IgG immunoglobulins and because they also enable asymptomatic and subclinical infections to be captured (
Xu et al., 2020
).Seroprevalence has already been determined in many countries (
Rostami et al., 2021
); there have been a few studies carried out at a population level in South America, including Argentina, Brazil (Hallal et al., 2020
; Silva et al., 2020
; Silveira et al., 2020
), Colombia (Mattar et al., 2020
), and Peru (Álvarez-Antonio et al., 2021
; Diaz-Velez et al., 2021
; Reyes-Vega et al., 2021
). Therefore, the current study aimed to select relevant studies and assess the pooled seroprevalence of the region.Methods
Studies about seroprevalence from Scielo, medRxiv/bioRxiv, and PubMed from South America were identified and selected. The studies included populations from regions (more than from institutions) with >500 inhabitants, carried out between April and September 2020. Information was included about the location, setting, period of study, used serological method (ELISA, LFIA, chemiluminescence, rapid tests), size of the study, and the value of the seroprevalence found, with their 95% confidence intervals (95% CI). Using the open software OpenMetaAnalyst®, a random-effects model meta-analysis was run to estimate a pooled seroprevalence.
Results
Nine studies from four countries were included: Argentina, Brazil, Colombia, and Peru, ranging from 716 individuals (Peru) to 31,165 (Brazil). Some areas, such as Iquitos (Peru) and Monteria (Colombia), had the highest peak of infection worldwide in July-August 2020. Table 1 shows that the seroprevalence values were high, with percentages reaching up to 70.0% (95% CI 67.0-73.4%) in Iquitos, Peru; Monteria (Colombia) and Buenos Aires (Argentina) showed seroprevalence above 50%. With the exception of Maranhao, Brazil, that showed the lowest values of seroprevalence (Table 1). The meta-analysis of such data enabled a pooled seroprevalence to be obtained, estimated at 33.6% (95% CI 28.6-38.5) (Table 1).
Random-effects model meta-analysis; τ2=0.006; Q=8968.13; I2=99.9; p<0.001. Preprints:Figar S, Pagotto V, Luna L, Salto J, Manslau MW, Mistchenko AS, et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. medRxiv 2020: 2020.07.14.20153858.Huamani C, Velásquez L, Montes S, Mayanga-Herrera A, Bernabé-Ortiz A. Population-Based Seroprevalence of SARS-CoV-2 Antibodies in a High-Altitude Setting in Peru. SSRN 2020: 3760458 doi 10.2139/ssrn.3760458
Table 1SARS-CoV-2 seroprevalence in South American populations.
| # | Location | Setting | Period | Method | N | Seroprevalence (95% CI) | Ref. |
|---|---|---|---|---|---|---|---|
| 1 | Iquitos, Peru | Province | July 2020 | Rapid test | 716 | 70.0% (67.0-73.4) | ( Álvarez-Antonio et al., 2021 ) |
| 2 | Monteria, Colombia | City | August 2020 | ELISA | 1,308 | 55.3% (52.5-57.8) | ( Mattar et al., 2020 ) |
| 3 | Buenos Aires, Argentina | Communities | June 2020 | ELISA | 873 | 53.4% (52.8-54.1) | (Figar et al., 2020) ⁎⁎ Preprints: Figar S, Pagotto V, Luna L, Salto J, Manslau MW, Mistchenko AS, et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. medRxiv 2020: 2020.07.14.20153858. Huamani C, Velásquez L, Montes S, Mayanga-Herrera A, Bernabé-Ortiz A. Population-Based Seroprevalence of SARS-CoV-2 Antibodies in a High-Altitude Setting in Peru. SSRN 2020: 3760458 doi 10.2139/ssrn.3760458 |
| 4 | Maranhao, Brazil | State | July-August 2020 | LFIA | 3,156 | 40.4% (35.6-45.3) | ()( Silva et al., 2020 ) |
| 5 | Cuzco, Peru | Province | September 2020 | Chemiluminescence | 1,924 | 33.1% (30.1-36.4) | (Huamani et al., 2020) ⁎⁎ Preprints: Figar S, Pagotto V, Luna L, Salto J, Manslau MW, Mistchenko AS, et al. Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research. medRxiv 2020: 2020.07.14.20153858. Huamani C, Velásquez L, Montes S, Mayanga-Herrera A, Bernabé-Ortiz A. Population-Based Seroprevalence of SARS-CoV-2 Antibodies in a High-Altitude Setting in Peru. SSRN 2020: 3760458 doi 10.2139/ssrn.3760458 |
| 6 | Lambayeque, Peru | Region | June-July 2020 | LFIA | 2,010 | 29.5% (27.6-31.5) | ( Diaz-Velez et al., 2021 ) |
| 7 | Lima, Peru | Province | June-July 2020 | LFIA | 3,212 | 20.8% (17.2-23.5) | ( Reyes-Vega et al., 2021 ) |
| 8 | 133 cities (26 states), Brazil | Country | June 2020 | LFIA | 31,165 | 2.8% (2.5-3.1) | ( Hallal et al., 2020 ) |
| 9 | Rio Grande do Sul, Brazil | State | May 2020 | LFIA | 4,500 | 0.2% (0.1- 0.4) | ( Silveira et al., 2020 ) |
| Pooled seroprevalence | 48,864 | 33.6% (28.6-38.5) | - | ||||
95% CI, 95% confidence interval; ELISA, enzyme-linked immunosorbent assay; LFIA, lateral flow immunoassay
Discussion
Without a doubt, seroprevalence of South American populations during the first wave were higher than those reported by European cities, where the highest seroprevalence was in the northern zone at 5.27% (95% CI 3.97-6.57%). Rates in South America were even higher than that initially reported by Iran with 22.16% (95% CI 18.7-26.0%) (
Rostami et al., 2021
). It is worth mentioning that the highest values, such as in Peru, Colombia, Argentina, and Brazil, came from low-income populations. The relationship with poverty has already been demonstrated in different studies. Beyond this, recent publications have suggested that herd immunity may not necessarily be enough to suppress the COVID-19 pandemic (Tkachenko et al., 2021
). The idea of herd immunity via natural infection rather than vaccination is a bit controversial, as it is unclear how long antibodies will last, and whether re-infection or re-activation of the virus can occur after the antibodies begin to lower in the body (Sharma et al., 2021
). Antibody titers can wane within weeks after infection and the magnitude of antibody neutralization in asymptomatic people decreases faster than in symptomatic people (Blasi et al., 2021
; Seow et al., 2020
).The data in all the studied regions were taken during the months where the highest infection peaks were reported. Therefore, it was expected that herd immunity would have been achieved, as expected for Maranhao (Brazil), during that time. However, they could have been overestimated, as expected, which apparently happened in Manaus (Brazil) and Iquitos (Peru) (
Sabino et al., 2021
), since until that moment it was unknown that new variants could appear, which would later refute this claim. Although many inhabitants had already been infected, a second wave appeared and even reinfections (1-2%) were reported, although are still under study. Furthermore, there is no clear definition of the proportion of a population vaccinated and infected at a given time, which is necessary for reaching “herd immunity”. Some publications have indicated that this may be as low as 10-25% (Kaushal et al., 2020
), while others as high as 60-70% (Gomes et al., 2020
; Silva et al., 2020
). Beyond that, given the high levels of seroprevalence found, no further cases should be in those areas; however, COVID-19 transmission and cases have still occurred.A limitation of these analyses is that retrospective data were used, ranging from May to September 2020. This is an important limitation, as the seroprevalence almost a year later, when vaccination had already begun in all of the studied countries, probably had an impact on the current situation. Another limitation is that databases that included some studies not peer reviewed (preprints) were used. Further analyses are expected after vaccination in the region, which is still slow, as in most countries, with <15% of people being fully vaccinated (July 8, 2021). Studies in the same areas after vaccination would be useful for comparison purposes. Additionally, although the mortality rates and their potential relationship with seroprevalence in the different countries were analyzed during the same period, is known that herd immunity can only be achieved with vaccination, as the natural course of infection would yield an enormous fatality rate; this has been the case in South America, with significant mortality.
It has also been postulated that developed immunity does not last long, probably more than a year. The application of vaccines could be an alternative to achieve herd immunity; however, continuous modifications will have to be developed against the new SARS-CoV-2 variants, and the vaccination process accelerated before cases increase again. Knowing the prevalence of COVID-19 in South America will still take time, as transmission of the Brazilian variant (Gamma, P.1) that is currently the most contagious lineage in this region is preventing herd immunity (although also Alpha and Delta variants are currently circulating, July 2021); in the meantime, continued use of masks, hand washing and social distancing in order to stop the transmission of the SARS-CoV-2 virus are required, and certainly increased vaccination. Variants are a growing concern for the potential compromise and reduction of efficacy of available vaccines (
Focosi et al., 2021
).Conflict of Interest
Dr. Rodriguez-Morales, report being medical advisor of Abbott Diagnostics for Latin America, outside the submitted work. The rest of the authors declare no conflict of interest..
Funding Source
Universidad Cientifica del Sur covered the APCs for this publication.
Ethical Approval
Not required.
References
- Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.Lancet Glob Health. 2021; 9: e925-e931https://doi.org/10.1016/S2214-109X(21)00173-X
- SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity.Respiratory medicine. 2021; 180106355
- SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020.Peer J. 2021; 9: e11210
- SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies.Viruses. 2021; 13: 1211https://doi.org/10.3390/v13071211
- Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold.medRxiv, 2020https://doi.org/10.1101/2020.04.27.20081893 (medRxiv)
- SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys.Lancet Glob Health. 2020; 8 (-e8): e1390-e1398
- Estimating the herd immunity threshold by accounting for the hidden asymptomatics using a COVID-19 specific model.PLoS ONE. 2020; 15e0242132
- Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries?.Open Forum Infect Dis. 2020; 7: ofaa550
- SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima.Peru. E Clinical Medicine. 2021; 34100801
- SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis.Clin Microbiol Infect. 2021; 27: 331-340
- Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence.Lancet. 2021; 397: 452-455
- Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.Nat Microbiol. 2020; 5: 1598-1607
- Combating COVID-19 pandemic in India: Demystifying the concept of herd immunity.J Family Med Prim Care. 2021; 10: 1515-1519
- Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhao.Rev Saude Publica. 2020; 54: 131
- Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil.Nat Med. 2020; 26: 1196-1199
- Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic.Int J Infect Dis. 2021; 107 (S1201971221003714): 116-120
- Time-dependent heterogeneity leads to transient suppression of the COVID-19 epidemic, not herd immunity.Proc Natl Acad Sci U S A. 2021; 118 (e2015972118)
- seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China.Nat Med. 2020; 26: 1193-1195
Article info
Publication history
Published online: July 11, 2021
Accepted:
July 8,
2021
Received in revised form:
July 6,
2021
Received:
May 8,
2021
Identification
Copyright
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
